| Followers | 535 |
| Posts | 76987 |
| Boards Moderated | 3 |
| Alias Born | 02/24/2010 |
Tuesday, December 25, 2012 1:05:46 PM
Pharmacokinetics Analysis Of First Dosing Results Positive_Cellceutix (CTIX) Boston Meeting With Merck (MRK) January 3rd Ventures Sierra World Equity Review
HEADLINE: Pharmacokinetics Analysis Of First Dosing Results Positive_Cellceutix (CTIX) Boston Meeting With Merck (MRK) January 3rd Ventures Sierra World Equity Review.
Remember when it happens, Sierra told you FIRST! Accurate call after accurate call, smart, single and sexy supermodel Sierra is SMOKING HOT in her predictions!! From FDA Drug Approvals and Trials to Potential Joint Ventures, Mergers, Buyouts, Acquisitions and Lawsuit Settlements..... get THE Scoop, always on the cutting edge of BIG Breaking News. Sierra covers all sectors from Biotech to Oil stocks, Gold stocks, Penny stocks on the OTC as well as the S&P, Nasdaq, Dow Jones and Amex. Famous for her HEADLINERS, Sierra made more correct calls in the last 5 months than all other Stock Reviews COMBINED. Click this link below for PROOF to previous accurate calls from Sierra:
HEADLINE: Pharmacokinetics Analysis Of First Dosing Results Positive_Cellceutix (CTIX) Boston Meeting With Merck (MRK) January 3rd Ventures Sierra World Equity Review.
Remember when it happens, Sierra told you FIRST! Accurate call after accurate call, smart, single and sexy supermodel Sierra is SMOKING HOT in her predictions!! From FDA Drug Approvals and Trials to Potential Joint Ventures, Mergers, Buyouts, Acquisitions and Lawsuit Settlements..... get THE Scoop, always on the cutting edge of BIG Breaking News. Sierra covers all sectors from Biotech to Oil stocks, Gold stocks, Penny stocks on the OTC as well as the S&P, Nasdaq, Dow Jones and Amex. Famous for her HEADLINERS, Sierra made more correct calls in the last 5 months than all other Stock Reviews COMBINED. Click this link below for PROOF to previous accurate calls from Sierra:
Recent MRK News
- Merck Announces Third-Quarter 2026 Dividend • Business Wire • 05/26/2026 05:28:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 08:21:18 PM
- Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer • Business Wire • 05/22/2026 11:55:00 AM
- Synergis Software lance Adept Cloud, une plateforme de gestion de documents d'ingénierie native du nuage conçue pour les industries à forte intensité d'actifs • PR Newswire (Canada) • 05/21/2026 05:42:00 PM
- Synergis Software Launches Adept Cloud, a Cloud-Native Engineering Document Management Platform Built for Asset-Intensive Industries • PR Newswire (US) • 05/21/2026 10:02:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/20/2026 08:23:39 PM
- Synergis Software Launches Adept Cloud, a Cloud-Native Engineering Document Management Platform Built for Asset-Intensive Industries • PR Newswire (US) • 05/20/2026 03:02:00 PM
- Synergis Software Launches Adept Cloud, a Cloud-Native Engineering Document Management Platform Built for Asset-Intensive Industries • PR Newswire (Canada) • 05/20/2026 03:02:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/18/2026 12:14:07 PM
- Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer • Business Wire • 05/18/2026 10:45:00 AM
- Form 13F-HR - Quarterly report filed by institutional managers, Holdings • Edgar (US Regulatory) • 05/13/2026 08:06:47 PM
- Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities • InvestorsHub NewsWire • 05/13/2026 01:00:00 PM
- Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities • GlobeNewswire Inc. • 05/13/2026 12:30:00 PM
- Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research at ASCO 2026 • Business Wire • 05/12/2026 10:45:00 AM
- Merck Scientists Publish Landmark Paper on Novel Method for Large-Scale Biocatalytic Synthesis of Investigational Oral PCSK9 Inhibitor, Enlicitide Decanoate • Business Wire • 05/07/2026 06:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 04:18:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 04:14:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 04:10:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 04:07:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 04:03:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 03:56:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 03:52:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 03:48:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 03:42:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 03:39:32 PM
